Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed)
- Agency
- National Institutes of Health
- NAICS
- 541714 - Research and Development in Biotechnology (except Nanobiotechnology)
- Posted
- 2023-08-24
- Deadline
- 2027-01-07